Hepatocellular carcinoma (HCC) is a common malignancy and one of the leading causes of
cancer-related death. The biological process of HCC is complex, with multiple factors …

Alpha-fetoprotein (AFP) is an oncofetal glycoprotein that has been used as a tumor marker
for hepatocellular carcinoma (HCC) in combination with ultrasound and other imaging …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

Background & Aims Hepatocellular carcinoma (HCC), the most common primary liver
cancer, remains a deadly cancer, with an incidence that has tripled in the United States …

Importance The combination of immune checkpoint inhibitors with antiangiogenic agents
has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC) …

Primary liver cancer is a challenging global health concern with an estimated more than a
million persons to be affected annually by the year 2025. The commonest type is …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

Background Most kidney transplant recipients with cancer stop or reduce
immunosuppressive therapy before starting treatment with an immune checkpoint inhibitor …

Immune-checkpoint inhibitor-based combination immunotherapy has become a first-line
treatment for several major types of cancer including hepatocellular carcinoma (HCC), renal …

Hepatocellular carcinoma (HCC) is one of the most lethal tumors in China and worldwide,
although first-line therapies for HCC, such as atezolizumab and bevacizumab, have been …